Lubrizol Corporation’s LifeSciences business unit, a total solutions provider for medical and pharmaceutical manufacturers, is investing US$10 million to significantly expand and strengthen the silicone operations of Vesta, a leading medical device contract manufacturer and a part of Lubrizol LifeSciences.
The company will add 71,000 square feet of space that complements the existing 126,000-square-foot operation of its silicone business.
In 2010, Vesta more than doubled its footprint at the silicone contract manufacturing site in Franklin, Wisconsin in the US. The current expansion supports LifeSciences’ long-term growth strategy to provide high-quality manufacturing for silicone implants and finished medical devices.
“When customers partner with Lubrizol LifeSciences, they benefit from working with us at every stage in their development process,” states Uwe Winzen, general manager, Lubrizol LifeSciences.
“With a long history of polymer expertise combined with recent investments, Lubrizol LifeSciences is positioned to offer full-service development for the next generation of medical devices, as well as long-term implantable and drug-eluting device innovations.”
The expansion adds 71,000 square feet of new space featuring product development, cellular manufacturing, and high-efficiency production lines, as well as separate Class 7 & 8 clean room space for the production of implants and drug-eluting devices. The expansion allows LifeSciences to capitalise on the strong local labor pool and technical expertise offered in the Wisconsin area.
“This new space covers immediate short-term needs, but also provides room for growth in the future. Customers can feel comfortable that we are able to handle both their current projects, as well as a significant increase in their future business efforts,” states Mark Stuart, Vesta general manager.